Charity registration number.. 1164238 Action Kidney Cancer Annu81 Report and Flnanclal Statements for the Year Ended 31 October 2024 Action Kidney Cancer Content$ {¢ontinued) Refgrence and Administrative Detail$ Trustees, Report 2to7 Stalemenl of Trustees, Responsibilitiès Indepandenl Examiners Report Stslement of Financial Activities 10 Balance Sheet 11 Note$ lo the Financial Statements 12to19 Action Kidney Cancer Reference and Adminlstratlve Details Chaimian A Thomas Tru$toes A Thomas J Larkin JPYM A Fielding S Tufajllc 1164238 Charlty R•glstratlon Number Prlnclpal Offlce 11th Floor 3 Piccadilly Manchester M1 3BN Indep•nd•nt Examlner Slockdale Accountants Ltd Sl Ingunger Offices Laniv81 Bodmin Comwall PL30 5HS Page 1 Annual Trustee Report Action Kidney Cancer For the Year Ending 31st October 20Z4 ACTION KIDNEY CANCER (Action Kidney Cancer is the working name of 'Kidney Cancer Support Network'l The Trustees present their report together with the financial statement for the year ended 31st October 2024. The financial statements comply with current statutory requirernents, the Charity's 8overnin8 document, and the Statement of Recommended Practice.. Accounting and Reporting by Charities p￿parIng their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland ISORP FRS 1021 (edition Ortober 2019, effective January 20191, and the Financial Reportin8 Standard applicable in the United Kingdom and Republic of Ireland IFRS 1021. Registered charity number: 1164238 in England Wales, SC051330 In Scotland Status.. Charitable Incorporated Or8anisation ICIOI Incorporated 3 November 2015 England Wales Status.. Charitable Incorporated organisation ICIOI incorporated 7 October 2021 Scotland Principal and re8iStered address: ACTION KIDNEY CANCER Kidney Cancer Support Network. Ilth Floor, 3 Piccadilly Place Manchester Ml 3BN Trustees Mr Andy Thomas-chair Professor James Larkin Mrjonathan Pym Professor Samra Turajlic Ms. Alison Fielding Mr5 Salena Mulhere Structure, 8¢)vernan¢e, and rnanagernent. ACTION KIDNEY CANCER began its work as a voluntary sUPPOrt or8anisation in 2006. As the Groups responsibilities, grew it was registered as a fomal charitable incorporated organisation ICIOI on the 3rd November 2015. The charity is managed according to it5 governing documents dated 3rd November 2015. The charity underwent a complete rebrandin8 during in 2021 and is now known by its working name ACTION KIDNEYCANCER. Where there is a requirement for new Trustees, they will be identified and appointed by the current Trustees. The ACTION KIDNEY CANCER management team is responsible for the induction of any new Trustees, and this will involve a briefing about Trustee responsibilit￿5. the governing documerst, and the adopted operating policies and procedures of the charity. All Trustees provide their services to the charity on a voluntary unpaid basis. The Trustees delegate day-to-day responsibility for the running of the charity to the Executive Officer and the management team who are accoLtntable to the Trustees and report to the Trustees throughout the year as required and at regular Trustee meetings. The Trustees have a duty to identify and review all risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees regularly review the risks that the charity may face, and the Trustees will continue to monitor the risks associated with its activities and continue to be vigilant as to other risks that might be associated with a charity providing SUPPOrt services to people affected by kidney cancer. The Trustees have agreed and adopted a series of operating policie5 to ensure the charity runs smoothly and complies with all charity commission requirements and legal responsibilities. The operatin8 policies are reviewed every two years and are available by written request to the ACTION KIDNEY CANCER management team. Some policies are available via the ACTION KIDNEY CANCER website. The Trustees declare as part of this annual return, that there are no serious incidents or other matters the Trustees should have reported to the Charity Commission. Charlty oblectlves and actlvltles To promote and protect the physical and mental health of patients with kidney cancer in the United Kingdom by.. l. The provision of information. support, education and practical advice to kidney cancer patient5. their families, and their carers 2. To advance the education and awareness of all matter5 relating to kidney cancer with the general public 3. Promoting and supporting research projects into the causes, diagrFosis, prevention, treatment. and cure of kidney cancer and disseminatin8 the results of such research. The Trustees meet a minimum of once a year, to discuss, agree and record charitable activities, strategy, funding priorities,'and OPe￿ting policies, including risk management. Project meetings are held throughout the year as required and/or as requested by the Trustees or monagement team. Public benefit The Trustees confirm that they have referred to the guidance provided by the charity commission's general guidance and advice on public benefit. In planning all activities including financial policies, the trustee5 confirm they have complied with the duty in section 17151 of the 2011 Charities Act and the Trustees are satisfied that all charitable activities during the year are for the benefit of the publit. Chair's Statement This year has been one of both consolidation and pro8res5 for Action Kidney Cancer. Despite sector-wide funding challen8es, our small team has worked tirelessly to ensure that kidney cancer patients and their carers receive the support, advocacy, and guidance they need. l am proud of what we have achieved and deeply grateful to every member of the management team who have worked so hard to make these achievements possible. About Action Kidney Cancer Artion Kidney Cancer is the UK'S only patient founded and patient-led kidney cancer charity. founded in 2006 and formally registered in 2015. We exist to ensure that all kidney cancer patients have access to the best possible care and treatment. We work to improve outcomes and the quality of life for kidney cancer patients. survivors, carers, and their families. Our charity is guided by a unique Board of Trustees that includes world-leading clinicians- Professor James Larkin (Royal Marsdenl and Professor Samra Turajlic {Francls Crlck Institute/Royal Marsden)- and Mr Andy Thomas, Mr Jon Pym, Mrs Alison Fielding BEM, and Mrs Salene Mulhere who are patients and carers with personal experience of kidney cancer. Thi5 ensures our charity is guided by people who have a shared goal to serve the kidney cancer community and to ensure the charity remains authentici prartical, and patient-centred. We provide.. Personalised, practical support for patients and carers navigating the complexities of the NHS High-quality, evidence-based patient information and resources in a variety of formats Advocacy on policy, treatment access and research Daily updates on news and advances through social media and our website Tailored support and resources that reflect the diverse cultural, ethnic. and socioeconomic back8rounds of people affected by kidney cancer. Main Achievements This Year Patient Support This year we have strengthened and expanded our support services to ensure patients and carers receive help when they need it most- Our online support forurn saw a significant increase in en8agement and new members. Our dedicated helpline continued to provide compassionate one-to-one 5UPPOrt. We increased our "Ask the Expert" videos to 21 in our online library. New patient information resources in patient friendly formats were added to our website, tailored to UK-specific needs. Our team presented at a 5UPPOrt meeting In Oxford and supported the launch of a new group in Surrey. We successfully launched the Renal Oncology Nurse Network supporting CNSS across the Country: hosting patient information days, distributing resources and opening new lines of communication. We partnered with Projert Flutter to create a launch video and supported their efforts to distribute butterfly bags and cushions to NHS hospitals. We authored two of four modules for the RCC4Nurses online course. We led the Coalition for Reducing Bureaucracy in cllnlcal trlals working group developing a patient-friendly ICF Ilnformed Consent Forml template. We participated in several Health Technology Assessment (HTA) submissions. Research Support & Involvement We have continued to influence and support kidney cancer research through strong patlent & public involvement.. UK Renal Oncology Group.. We provide a full secretariat support for this newly formed group of renal clinicians focused on non.commercial research priorities following the demise of the NCRI. Responslbillty for promoting the International Kidney Cancer Coalition Global Patlent Survey, achievin8 197 UK responses-one ofthe highest response rates. We manage the Patient Involvement and Public engagement for the Global CARE-I Cllnical trial, a large cross border European biomarker study, including establishing an International Patient Advisory Board. Promoted PPIE best practice and supported funding applications across the UK. Participated in: NICE RCC Guidellnes Commlttee North West Cancer Research INWCRI- Immunotherapy Project Steerin8 Committee Trial Management Group for REFINE cllnlcal Trlal Patient member of Trlal management group for an Internatlonal consensus paper on Core Outcomes for RCC Membership of the campaign Reduclng Bureaucracy In Cllnlcal Trlals Celebrated the publication of the OPTIC abstrart and research paper Ioct 20241. Policy and Advocacy We have maintained a strong presence in national and re8ional advocacy: Welsh Cancer Alllance.. Collaborating with 20+ organisation5 to influence cancer care in Wales. Scottlsh Cancer Coalltlon.. Working together to ensure people affected by cancer in Scotland receive the best possible support and treatment. Cancer52: Representing rare and less common cancers,. led the Access to Clinical Trials Working Group and participated in the BIG Cancer52 Conversation 2024. WECAN Academy.. Presented on patient-led advocacy at this leading European training initiative for advocates. National Kldney Cancer Audit.. Provided patient representation for quarterly reports and the State of the Nation Report (Sept 2024). Supported One Cancer Voice, a joint call from 60+ charities for a national cancer strategy in summer 2024. Continued our campaign for treatment breaks for patients receiving TKIS and immunotherapv. Awareness & Education Awareness-raising continues to be an important element of our work Supported and promoted World Kidney Cancer Day (WKCD) 2024, launching a dedicated webpage and coordinated with several NHS hospitals and research institutions. Partnered with organisations such as IKCC, FROG, the Welsh Cancer Alllance, and the Scottish Cancer Coalition. Presented at various pharmaceutical companies to improve understanding of kidney cancer. Hosted a patlent information stand at The Christie Hospital. Presented at the IKCC Global Kidney Cancer Summit (South Korea) on the emotional challen8es of diagnosis and communication. Financial Overview Llke many In the UK charity sector, and wider across Europe and North Amerlca. we experienced reduced funding from pharmaceutical companies in 2024. This trend is echoed across health related charities in many Countries and hi8hlights the need for dlverslflcatlon of income. To that end: We strengthened advocacy and research partnershlps Our reserve funds are now held in Interest-bearlng accounts We delivered successful fundraising campai8ns, includin8: Annual Northern soul fundralser Annual Golf days Sponsored walks and skydlves School-led event London Memorlal concert Our popular"Gift a Heart" campal8n continues We are deeply grateful to every volunteer. donor and supporter who makes our work possible. Looking Ahead Our priorities for the year ahead include: Building sustainable, diversified Income sources Continuing to grow our patient, carer and family support network Increase our partnership working with research institutions to provide patient and public Involvement Advocating for better aLcess to care and trials across the UK. As we move forward into 2025, we remain steadfast in our belief that no one affected by kidney cancer, whether they are patients, carer5, or family members, should ever feel they have to face kidney cancer alone. ## **Action Kidney Cancer** ## **Statement of Trustees' Responsibilities** The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations. The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to: - select suitable accounting policies and then apply them consistently; - observe the methods and principles in the Charities SORP; - make judgements and estimates that are reasonable and prudent; - state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and - prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business. The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. Approved by the trustees of the charity on 30th June 2025 and signed on its behalf by: A Thomas Chairman and trustee Page 8 Action Kidney Cancer Independent Examinevs Report to the trustees of Action Kidney Cancer I report to the trusleeg on my examination of the accounts of Action Kidney Cancer for thè year ended 31 October 2024. Responsibilities and basi$ of report As the ¢harity trustees of Action Kidney Cancer you are responsible for the preparation of the accounts in accordan￿ wlh the requirements of the Charitses Act 2011 I'the Act'i. I report in respect of my examination of the Action Kidney Cancer's a￿O￿ntS carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directy'ons given by the Charity Commission under section 14515llbl of the Act. Independent examIne￿$ statement I have completed my examination. I confirm that no material matters h8ve come lo my attention in connection with the examination giving me cause lo believe t+)al in any material respect.. 1. accounting records were not kept in respect of Action Kidney Cancer as required by section 130 of the Act., or 2. the accounts do not accord with those records.. or 3. the accounts do not comply with Ihe accounting requirements conceming the lorrll and conlenl of a￿O￿ntS set out in the Charities (Accounts and Reports) Regulations 2008 Dlher than any requirement that the accounts give a 'lrue and fair view. which is not a matter considered a5 part of an independenl examination. I have no concems and have come across no other matters in connection wth the examination to whi¢h attentK)n should be drawn in this report in order to enable a proper understanding of the ac¢ounls lo be reached. Hay FMAAT Sl Ingunger Offices Lanivel Bodmin Comwall PL30 5HS ,lola5 Page 9 Action Kidney CanGer Statement of Financial Activities for the Year Ended 31 October 2024 Unrestricted funds Restrict8d funds Total 2024 Note Income and Endowmenls from: Donations and legacies Investment income Other income 46.610 65 32.656 36,210 82.820 32,656 Total income 79,331 36,210 115,541 Expenditure on: Charitable activities {91,8801 120,9531 1112.8331 Total expenditure 91,880 20,953 112,833 Nel {expendilurellincome 12,549 15,257 2,708 Nel movement in funds 112,549) 15,257 2.708 Reconciliation of funds Total funds brought forward Totsl funds carried forward 288.824 288,824 276,275 15.257 Unrèstricted fund$ 291.532 Total 2023 Note Income and Endowments from: Donations and legacies Othèr in¢om8 104,633 30.064 104,633 30,064 Total income 134,697 134,697 Expenditur• on: Charitable activities 100.582 100,582 Total expenditure {100,5821 1100,582 Net income 34,115 34,115 Nel movement in funds 34,115 34,115 Reconciliation of fund$ Total funds brought lorward Total funds carried forward 254,709 254,709 288,824 288,824 All of the charity's activities derive from continuing operations during the above ts¥o peritxls. The funds breakdown for 2023 is shown in note 11. The notes on pages 12 to 19 form an int￿ra1 part of these financial statements. Page 10 ## **Action Kidney Cancer** ## **(Registration number: 1164238) Balance Sheet as at 31 October 2024** |**Current assets**
Debtors
Cash at bank and in hand
**Creditors: Amounts falling due within one year**
**Net assets**
**Funds of the charity:**
**Restricted income funds**
Restricted funds
**Unrestricted income funds**
Unrestricted funds
**Total funds**
**Note**
8
9
10
11|**2024**
£
9,107
290,122
299,229
(7,697)
291,532
15,257
276,275
291,532|**2023**
£
20,645
275,489
296,134
(7,310)
288,824
288,824| |---|---|---| |||288,824| The financial statements on pages 10 to 19 were approved by the trustees, and authorised for issue on .30th June 2025 and signed on their behalf by: A Thomas Chairman and trustee The notes on pages 12 to 19 form an integral part of these financial statements. Page 11 Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2024 1 Accounting policies Statement of compllance The financial statements have been p￿pared in accordance wtth the second edition of Ihe Charities Statement of Recommended Practice issued in Ociober 2019, Financjal Reporting Stsndard applicable in the United Kingdom and Republic of Ireland IFRS 102) and the Charilies Act 2011. Basis of preparation Action Kidney Cancer meets the defin￿on of a b￿￿rit entity under FRS 102. The accoun15 (financial statements) have been prepared under the historical cost convenbon b*ilh items fecognised al cost or transaction value unless otherwise stsled in the relevant nole{s) lo these accounts. G¢lng concern The Iruslees consider that there a￿ no material un￿rtaIntieS at￿ut the charitys ability to u)nlinue as a going concem. Income and endowments Voluntary income including donations. grfts, Iwes aThY grants that provide core fvndlng or are of a general nalure is recognised when the charity has enb"tJement to the income. it is probable that the income will be recetved arHJ the amC￿nt (an be measured with suffic*nt reliability. Donations and legacies Donations and legacies are reccgnised on a receivable basis when receipt is probable and the amount can be reliabty measure(J. Grants receivable Grants are recognised when the tharity has an entidement lo the funds and any conditions linked to th& grants have been met. Where perfom)ance conditions are attached to the grant and are yet lo be mel. the income is r8crYJnised 8s a liability and indudeij on the balarKe sheet as deferred inLyJrne to be ￿lease￿. Invo$tsnent income Dividends are reccKJnised once Ihe divideTrJ has been decLared and notification has been received of the dividend due. Expenditure All expenditure is reeognised once there a legal or conslwctive obligation lo that expenditure, it is probable settlement is required and the amount can be measured ￿lIablY. All costs are alkjcated to the applicable expenditure heading that aggregate similar costs lo that category. Where cosls cannot be directly attributed to partr"¢xJlar headings they have been alhxated on a basis consistent with the use of resources, with central stsff costs allocated on the basis of time spent. and depreuation ¢harges allocated on the wtion of the assel's use. Other support costs are allwled based on the spread of staff costs. Page 12 Action Kidney Cancer Notes to the Flnancial Statements for the Year Ended 31 October 2024 (continued) Charitable activltles Charitable expenditure comprises those costs inCUr￿d by the charity in Ihe delivery of its activili8s and services for its beneficiaries. 11 includes both costs that can be 8llocaled direcily to such activities and those ¢05t5 of an indirect nature necessary to 5UPPOrt them. Taxation The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a Charrtable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxats.on in restecl of income or capital gains received withFn categories covered by Chapter 3 Part 11 of the CO￿orab.0n Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exctuswely to charitsble purposes. Depreciatlon and amortl$atlon Deprecialion is provided on tangible fixed assets so as to wrtte off the cost or valuation. less any estsmaled residual value, over their expected useful ec1￿MI¢ lrfe as folkx¥s: Trade debtors Trade debtors a￿ amounts due from cUSton￿lS for merchandise sold or services perfomied in the ordinary course of business. Trade debtor5 are recojnised initially at the transaction wice. They are subsequenlty measured at amortised cost using effective interest methc*J, less provision for impairment. A provision for the impairment of trade debtors is established when there is obJ"ective e￿den￿ that the charity will not be able lo collect all amounts due aCC￿rding to the original terms of the receivaues. Cash and cash equivalents Cash and cash equivalonts comprise cash on hand and call deposits, and other short-terni highly liquid investments that are readily convertible to a known amount of cash and are subjecl to an insignificant risk of change in value. Trade creditors are obligations to pay for gc(wJs or Servi￿ that have been acy]uired in the ordinary course of business from suppliers. Accounts payable a￿ dassified as cutrent liabilities rf the does not have an une4)ndilional right. al the end of the ￿porting peri(Kl, to defer settlement of the creditor for al least twelve months after the ieportip.g date. If there is an uncondilional right to defer Set￿ment for at least velve months after the reporting date, they a￿ presented as nonrrowing. Interest expense is recognised on the basis of the effective interest method and is induded in interest payable and similar charges. Borrowings are classrfied as ¢￿￿ent liabilities unless the charity has an unconditional right lo defer settlement of the li8bility for al least ￿efve months after the reporbng date. Fund structu Uniestricted income funds are general fvnds that are availabk for use at the trustees discretion in furtherance of the objectives of the charty. Restricted income funds are those donated for use in a particular area or for speufic purposes, the use of which is restricted to thal area or purpose. Flnancial Instruments Classlftcation Financial assels and financial liabilities are recryJnised when the charity becomes a party to the contractual provisions of the instrumenl. Financial liabilities and equrty instnjments ale classified accDrding to the substanc£ of the conlr8CtU81 arrangements entered into. An equity instrument is any contract that eVIden￿S a residual interest in the assets of the charrty after deducting all of its liats"lilw. Recognition and measurement I rinancial assets ar*J liabilit￿ are initialty measured at transa¢tK>n Pri￿ lincluding transaction coslsl. except for those financial assets classified as at fair value through profit or loss. which are initially measured at lair value Iwhich is noimally the trans8Ction price exduding transaction costs), unless the arrangement eonstrtutes a financing transaction. If an arrangement constitutes a financing transaction, the finanaal asset or fin8n¢ial liability is measured al the present value of the hjture payTnents discounted al a market r8te (rf interest for a similar debt instrument. Financial assets and liabil￿eS are only offset in the ststemerbt of financial rM)sition ￿en. and cmly when the￿ exists a legally enforceable right to set off the recognised amounts and Ihe charity intends either to settle on a nel basi5. or lo realise the asset and settle the l￿bilty gmullaneousW. Finan¢ial assets are dereco9nised when and only when al the contractual rights lo the cash flows from the financial asset expire or are settled, bl the thartty Ir3nsfer5 to another paty substantially all of the risks and rewards of ownership of the finanoal asset. or c} the charity, despite having ￿taIned some. but not all, significant risks and fewafds ol OWne￿hIp. has transferred control of the asset to another paty. Financial liabilities are derecognised cmly w￿n the oblYJatvJn specified in the CA)ntra¢t is discharged, cancelled or expiras. Page 14 Action Kidney Cancer Notes to the Financial Slatements for the Year Ended 31 October 2024 (continued) Debt instwments Debt instruments which meet the conditions are subsequenuy measured al amortised cost usiThJ the effective Inte￿St method.. la) The contractual retum to the hokleT Is {il a fixed am(wnt,' lill a [￿sitiVe fixed rale or a positive variable rate.. or {iiil a combinatK)n of a rm)$￿Ve rx a negth.ve fixed rate and a posilNe variable rate. Ibl The contract may provide for repayments of the principal or thg relum to the holder {but not tK)thl to be linked to a single relevant observable index of general price inflation of Ihe currency in which the debt instrument is denominated, provided such link5 are not leveraged. Icl The contract may provmje a deterniinabk variation of the retum to the holder during the life of the instrument. provided that li) the new rate satisfies c4)ndrtKJn lal and the variation Is not contingent on fulure events other than 11} a Change of a contractual variable rate., 121 to protect the holder against credit delerioralion of the issuer.. 131 changes in lev￿ applied by a central bank or arising from changes in relevant taXat￿n or law: or lill the new rate is a market rate of interesl and satisfies condition {a). Idl There is no contractual provision that couhj. by rt5 terms. result in the holder losing the prinripal amount or any interest attributsble lo the current peri(￿ or wor penods. (el Contractual provisions Ihal pem)il the issuer to prepay a debt instrument LY pemiit the holder lo pul Il back to the issuer befo￿ maturity are nol ￿ntingent on future evenls, other than to piotect the holder against the credit deteriorats.￿ of the issuer or a change in control of the issuer, or to prolect the holder or issuer against Changes in levies applied by a Central bank or arising from changes in relevant laxati￿ or law. In Contractual provisions may permit the extension of the term of the debt instrument, provided that the ￿tUrn to the holder and any other contractual provigons applicable during the extendgd torn1 satisfy the conditions of paragraphs lal to Icl. Debt instruments that are classrfied as payable or receivable wthin one ￿ar on inilk41 reccgnit•Jn and which meet the above conditions are measured at the und1S￿Vnted amount of the cash or other consideration expected to be paid or received. net ol impaim*nl. With the exception of some hedging instruments. other debt instnjmenls nol meeting these (yjnditions are measured 8t fair value through profft or ￿ss. Commitments lo make and ￿￿1VeI08nS which meet the conditions mentionetl above are measured al cDsl (which may be nill less impairmenl. Investments Investments in nonrycLJnvertible preference shares arKI non-pultable ordinary or P￿le￿n￿ shares (where share5 are publicly traded or their fair value is reliably measurable) are measured al fair value through profit or loss. wtte￿ fair value cannot be measured reliably. investments are rneasured at LX)sl less impaim)ent. Investments irF subsidiaries and assc¢i8tes are measured at cost less impaim)ent. For investmen15 in subsidiaries acquired for consideration including the issue of shares qual￿.ng for merger reliel, cost is measured by reference to the nominal value of Ihe shares issued plus fair value of other consideration. Any premium is ignored. Page 15 Adion Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2024 (eontinued) Dertvallve flnan¢lal Instruments The charity uses derivatsve financial instruments to ￿duce exposure to f￿ign exchange risk and interest rale movements. The charity does nol hold or issue derivative fin8ncAal instruments for speculative purtK)ses. Derivatives are initially recogrbised al fair value al the dale a derivative contract is entered into and a subsequently remeasured lo their fair value al eath rewrting date. The resulting gain or loss is r8cognised in statement of finanaal ath"vrties immediately unless the derivative is designated and effective as a hedging instrument. in which evenl the timiThJ of the recognition in statement of finan(ial activities depends on the nature of the hedge relationship. Fair value measurement The best ewdence of fair value is a quoted pri￿ for an identical asset in an active market. When quoted prices are unavailable. the pri￿ of a reL%nt transaction for an identical asset provides eviden￿ of fair value as long as there has not been a significant change in e￿nOMiC Clrcumstsn￿S or a signtficant lapse of time since the transaction took plaf*. If the market is not active and Tecenl transactions of an identical asset on their own are r￿l a gL￿d estimale of fair value, the fair value is estimated by using a valuatKJn technique. 2 Income from donations and lega¢les Unrestricted funds General Rostricted tunds Total funds Donations and legacies- DonatK)ns from individuals Grants, including capital grants: Grants from other chanl 41.610 41,610 36.210 41,210 Total tor 2024 46,610 36.210 82,820 Total for 2023 104,633 104.633 3 Investment in¢om• Unrn$tricted funds General Totsl funds Interest receivable a￿1 similar incAJme', Inter8st receivable C￿ bank deposits 6S 65 Total frjr 2024 65 Page 16 Action Kidney Cancer Notes to the Flnancial Statements for the Year Ended 31 October 2024 (continued) 4 Olhor Income Unrestrlcted funds General Total fund$ Advocacy Fees 32,656 32,656 Total for 2024 32,656 32.656 Total for 2023 30,064 30,064 5 Expendlture on charitable activili¢s Unrestricted funds Genernl Restrictgd funds Total funds Nots support of kidney cancer patwts Governance costs 91,881 20,953 112.834 Total for 2024 91.880 20,953 112,833 Total for 2023 100.582 100.582 6 Trustees remuneration and expenses No Iruslees, nor any ￿[sonS C￿nected with them. have received any remuneration from the charity dunng the year. No trustees have r8ceNed any reimbursed expenses or any other berth from the charity during the year. 7 Taxation The charity is a registered charity and 15 therefrKe exempl from tsxab"cfft. 8 Dgbtors 2024 2023 Trade debtors Prepayments 4.441 4,666 400 20,245 9,107 20,645 Page 17 Action Kidney Cancer Notes to the Financial Ststements for the Year Ended 31 October 2024 (continued) 9 Cash and cash equlvalents 2024 2023 Cash at bank 29).122 275,489 10 Creditors: arnounts falling due within one year 2024 2023 Trade creditors Accruals 7,597 100 7.210 too 7,697 7,310 11 Funds Balance at 1 November 2023 Incoming re$our¢e$ Resourcès expend•d Balance at 31 October 2024 Unrestri¢tsd General 288,824 79,331 (91,880) 20.953 276,275 Restrlcted 36,210 15,257 Total fund$ 1288.824 115.541 112.833 291,532 Balance * 1 NoveM￿r 2022 Incoming rnsoure•$ Resources •xpendod Balanco at 31 October 2023 Unrestricted General 254,709 134,697 {100,582 288,824 Page 18 Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2024 (continued) 12 Analysls of net assets between funds Unr•strided Total funds 2024 General Current assets Current liab11￿.es 299.229 7.697 299,229 17.697 291,532 Totsl nel assets 291,532 Unrestricted Totsl funds 2023 General Current assets Current Iiabilth'es 296.134 7,310 296,134 7.310 Totsl nel assets 288,824 288.824 PaJ8 19 Action Kidney Cancer Detailed Statement of Financial Activities for the Year Ended 31 October 2024 Total 2024 Total 2023 Income and Endowments from: Donations and legaaes lanalysed below) Investment incorne {anal￿ed bel(Mtl Other income lanaly5ed below) 82,820 65 32,656 104.633 30,064 Total income 175,541 134,697 Expenditure on: Charitsble aclivilies lanalysed belc)wl 112,833 100,5821 Totsl exFenditure 112.833 100,582 Nel income 2,708 34.115 Nel movemenl in funds 2.708 34.115 Reconciliatlon of funds Total funds brought fon¥ard Total funds carried fofward 288,824 254,709 291,532 288,824 This page does not form part of Ihe stal¥Jtory financial statements. Page 20 Action Kidney Cancer Detailed Statement of Financial Activities for the Year Ended 31 October 2024 (continued) Totsl 2024 Total 2023 Donations and legacies Appeals and donations Grants - other agencies Reslncled income 41.610 5.000 36.210 29,633 75.000 82,820 104,633 Investment In¢ome Bank interest ￿CeIVable 65 65 Other income Advocacy fees 32,656 30,064 32.656 30,064 Charitable activities Rent Insurance Advo¢acy and medical relations Telephone and fax Communications Office and administration Websf(e and maintenan PrinlirKJ, postage and statKJnery Patient Support Sundry expenses Project management Travel and subsislen Marketing Material Fundraising costs Patient Days Events Charity meeting AcLountancy fees Legal and professional fees Restricted expenditure All Giving plarfomi charges Depreciation of office equipment Office and administiation 11,0351 11741 130.0331 11661 (11.2421 17,351} 17,6631 126 115,625 1251 {1.9081 12.6331 14991 (12.3401 4,711 12,5361 1660 12 128,3141 11681 {11,1851 18.6571 17.7441 114,7501 12401 17,8381 11.0871 {23 11.9701 15.0711 11001 11,1801 11001 11,567 120.953 {1.6691 11,3641 12431 112.833 100,582 This page doe5 fK)t f¢ym part of the statulory financial statements. Page 21